Loading clinical trials...
Loading clinical trials...
The major goal of this proposal is to characterize the ability of epicatechin which a component of dark chocolate to improve the 1. structural and functional features of skeletal muscle (SkM) 2. exercise capacity (as assessed by VO2 max) 3. parameters of diastolic heart function (as assessed by echocardiography) We propose that a 3 month treatment with epicatechin (through CocoaVia® capsules) will lead to a significant improvement in exercise capacity and diastolic function.
Patient Inclusion/Exclusion Criteria: 1. New York Heart Association Class II/III HF with preserved ejection fraction (EF) of \>50%. 2. Nonsmokers 3. Subject not taking Coumadin, Xarelto, Prasugrel or Pradaxa. Patients on Plavix for drug eluting stent will not be excluded. 4. Ages between 40-65. We will exclude any women of child bearing potential
Age
40 - 60 years
Sex
ALL
Healthy Volunteers
No
University of California, San Diego
La Jolla, California, United States
Start Date
January 1, 2014
Primary Completion Date
April 1, 2015
Completion Date
April 1, 2015
Last Updated
June 3, 2015
7
ACTUAL participants
CocoaVia
DIETARY_SUPPLEMENT
Lead Sponsor
University of California, San Diego
NCT07191730
NCT07484009
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions